Tag Archives: Type 2 Diabetes Patients

Novo Nordisk’s Oral Semaglutide Reduces Cardiovascular Risk by 14% in Type 2 Diabetes Patients, SOUL Trial Shows

(IN BRIEF) Novo Nordisk’s SOUL trial has shown that oral semaglutide reduces the risk of major adverse cardiovascular events (MACE) by 14% in adults with type 2 diabetes and established cardiovascular disease or chronic kidney disease. The trial involved 9,650 … Read the full press release